Hong Kong · Delayed Price · Currency is HKD JW (Cayman) Therapeutics Co. Company Description
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China.
The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer.
It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection (“relma-cel”) as a potential treatment for systemic lupus erythematosus (“SLE”), and progressed development of products for the treatment of solid tumors, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease.
The company’s products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma; and JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune diseases.
It is also developing JWATM204 and JWATM214 for treating hepatocellular carcinoma (HCC); JWATM203 for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in pediatric patients; JWATM213 for treating HCC; JWTCR001 for the treatment of various solid tumors; and JWCAR031 for the treatment of small cell lung cancer.
In addition, the company engages in drug research and development; medical research and experimental development; import and export handling; and clinical trial and CRO, as well as investment holding activities.
JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
| Country | Cayman Islands |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 314 |
| CEO | Feng Tian |
Contact Details
Address: Building B Shanghai China | |
| Phone | 86 21 5078 3699 |
| Website | jwtherapeutics.com |
Stock Details
| Ticker Symbol | 2126 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG5210T1040 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Feng Tian | Chief Executive Officer and Executive Director |
| Dr. Yiping Li M.D. | Co-Founder and Director |
| Jihua Qin | Vice President and Head of Marketing and Medical Affairs |
| Dr. Mark J. Gilbert M.D. | Senior Advisor and Acting Chief Medical Officer |
| Chunan Chen | Senior Vice President |
| Zhen Xia | Head of Clinical Science Department |
| Ka Man Ng A.C.I.S., A.C.S. | Company Secretary |